CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

HYDERABAD: Dr Reddy’s Laboratories SA, the wholly-owned Swiss subsidiary of Hyderabad-based pharma biggie Dr Reddy’s ...

Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: ...

AgreementLotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region 05.02.2025 / 06:30 CET/CESTThe issuer is ...

Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe: Our Bureau, Bengaluru Thursday, February 6, 2025, 17:20 Hrs [IST] Dr Reddy’s La ...

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...

Dr Reddy’s Laboratories has signed a licensing deal with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar of Johnson & Johnson’s (NYSE: JNJ) Darzalex (daratumumab) for ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.53 billion, has been positioning itself for a new phase of multi-year growth ...

The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...

What will be important about biosimilars market penetration will be such rules that really push prescribers and payers to go for lower priced products compared with originator products.